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ABSTRACT
Despite aptamers are very promising alternative to
antibodies, very few of them are under clinical trials
or are used as drugs. Among them, NU172 is cur-
rently in Phase II as anticoagulant in heart disease
treatments. It inhibits thrombin activity much more
effectively than TBA, the best-known thrombin bind-
ing aptamer. The crystal structure of thrombin-NU172
complex reveals a bimodular duplex/quadruplex
architecture for the aptamer, which binds throm-
bin exosite I through a highly complementary sur-
face involving all three loops of the G-quadruplex
module. Although the duplex domain does not in-
teract directly with thrombin, the features of the
duplex/quadruplex junction and the solution data on
two newly designed NU172 mutants indicate that the
duplex moiety is important for the optimization of
the protein-ligand interaction and for the inhibition
of the enzyme activity. Our work discloses the struc-
tural features determining the inhibition of thrombin
by NU172 and put the basis for the design of mutants
with improved properties.
INTRODUCTION
Despite the widespread use of antithrombotic drugs for the
prevention and treatment of arterial and venous thrombo-
sis, thromboembolic diseases continue to be a major cause
of death and disability worldwide (1,2). For this reason,
further efforts must be made to combat these disorders.
Oligonucleotide aptamer technology is extensively used to
modulate the function of most of the factors involved in
coagulation (3), the complex process by which blood forms
clots upon the damage of a blood vessel wall. Coagulation
pathway is the final step of haemostasis and is directed to-
ward creating fibrin through a cascade of events, which are
regulated by several coagulation factors (4). Anticoagulant
nucleic acid aptamers are short, single-stranded DNA or
RNA sequences that bind to coagulation factors with high
affinity and specificity through their three-dimensional
structures. They hamper the protein–protein recognition
events that are the key processes of the coagulation cascade
and have the unique ability to be therapeutically regulated,
by either controlling their circulating half-life or reversing
their function with an antidote (3,5–7). Some of them are
evaluated in clinical studies (8–12). Thrombin is the central
orchestrator of the coagulation cascade; it catalyses the
conversion of fibrinogen to fibrin and activates proco-
agulant factors V, VIII, XI and XIII (13). Additionally,
when bound to thrombomodulin, it activates protein
C, an anticoagulant zymogen (14). The delicate balance
between the two functions in the normal physiological
state prevents clot formation in undamaged vessels and
triggers the coagulation cascade in the damaged ones (15).
Thrombin capability to perform such different functions
relies on the ability to recognize a large variety of sub-
strates, inhibitors and cofactors (16). This ability is finely
regulated by two distinct regions on the protein surface,
known as exosites I and II, which allosterically modulate
thrombin function, thus providing specificity to the pro-
teolytic activity of the protein (15). Therefore, thrombin
represents an attractive target for the development of
agents that effectively interfere with thrombogenesis. The
most studied anti-thrombin aptamer is TBA (also known
as HD1) (5′-GGTTGGTGTGGTTGG-3′), a DNA 15mer
oligonucleotide that inhibits thrombin clotting activity at
nanomolar concentration (17). This oligonucleotide adopts
a unimolecular antiparallel G-quadruplex structure, com-
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posed of two TT loops and a TGT loop protruding from
the opposite sides of a two G-quartet moiety (18,19).
TBA is a strong anticoagulant in vitro, where it inhibits
thrombin-catalysed activation of fibrinogen and thrombin
induced platelet aggregation (17). Moreover, it is able to
bind both free and clot-bound thrombin (20,21). For these
reasons, TBA was considered as a promising anticoagulant
drug and, with the name ARC183, reached Phase I clinical
trials (Archemix Corp. and Nuvelo) as an anticoagulant
for potential use in acute cardiovascular settings, such as
coronary artery bypass graft (CABG) surgery. The finding
that the amount of drug needed to achieve the desired
anticoagulation for use in CABG surgery corresponds to a
suboptimal dosing profile blocked the TBA development
(3,22). Efforts have then been focused on a second-
generation aptamer, designated NU172 (or ARC2172)
(5′-CGCCTAGGTTGGGTAGGGTGGTGGCG-3′),
which possesses a pharmacokinetic profile similar to that
of TBA but with a significantly higher potency as an
anticoagulant. NU172 has an IC50 value of 5–10 g/ml
in plasma in an ecarin clotting time assay obtained by
using thromboelastography (23). Currently, NU172 is the
only thrombin binding aptamer evaluated in Phase II
clinical trials (ClinicalTrials.gov identifier NCT00808964)
for anticoagulation in heart disease treatments by ARCA
Biopharma, Inc. (3,11,24,25). It induces a short-acting
anticoagulation effect and is well tolerated without serious
adverse responses (12). Furthermore, due to its high affinity
toward the target protein, which is about one order of mag-
nitude greater than that of TBA (26), NU172 represents a
promising biorecognition element for the development of
high performance thrombin aptasensors (27).
Here, we present the crystallographic structure of the
thrombin-NU172 complex that provides an accurate de-
scription of the mixed duplex/quadruplex fold of the ap-
tamer and its mode of binding to thrombin exosite I. In
particular, the details of the G-quadruplex loop organiza-
tion on the protein surface suggests an interesting link to the
specific antithrombotic properties of the aptamer. This has
received further support by the folding and anticoagulation
studies on NU172 and two variants. From these studies, it
emerges the importance of the mixed duplex/quadruplex
organization on modulating the NU172 properties.
MATERIALS AND METHODS
Sample preparation and crystallization
The human D-Phe-Pro-Arg-chloromethylketone (PPAC
K)-inhibited thrombin was purchased from Haematologic
Technologies (USA). The oligonucleotides (Supplementary
Figure S1) were purchased from Sigma-Aldrich (United
Kingdom).
Two stock solutions of NU172 were prepared at a con-
centration of about 0.1 mM, dissolving solid lyophilized
oligonucleotides in 10 mM potassium phosphate buffer pH
7.4 and 100 mM KCl (K buffer) or 10 mM sodium phos-
phate buffer pH 7.4 and 100 mM NaCl (Na buffer). In or-
der to induce folding, all aptamer samples were annealed by
heating to 90◦C for 5 minutes and then slow cooling down
in 50–60 minutes and storing at 20◦C overnight.
A standard protocol was followed for the preparation of
the complexes between thrombin and NU172 in presence
of potassium (thrombin–NU172–K) or sodium (thrombin–
NU172–Na) ions (19,28–31). The thrombin-NU172 com-
plexes were concentrated to about 10 mg/ml using 10 kDa-
cutoff Centricon mini-concentrator (Vivaspin 500, Sarto-
rius, Goettingen, Germany) and a refrigerated centrifuge
(Z216MK, Hermle Labortechnik, Wehingen, Germany).
An initial extensive screening of sitting-drop crystalliza-
tion experiments at 20◦C in 96-well plates (Greiner Bio-One,
Monroe, NC, USA) was carried out using an Automated
Protein Crystallization Workstation (Hamilton Robotics)
and precipitant solutions of a commercially available crys-
tallization screen (Hampton Research Index). Optimiza-
tion of starting conditions was performed by hanging drop
vapour diffusion method mixing 0.5 l complex solution
with 0.5 l reservoir solution at 20◦C. Crystals suitable for
X-ray diffraction data collection grew, for both complexes,
in 50% (v/v) Tacsimate™ pH 7.0 (Supplementary Figure S2)
(32).
Data collection, structure determination and refinement
Thrombin–NU172–K diffraction data were collected at
the Institute of Biostructures and Bioimages (IBB), CNR,
Naples, Italy, using a Saturn944 CCD detector. The X-
ray radiation used was CuK radiation ( = 1.5418 A˚)
from a Rigaku Micromax 007 HF generator. Thrombin–
NU172–Na diffraction data were collected at the ID30A-
1 beamline of European Synchrotron Radiation Facil-
ity (ESRF), Grenoble, France, using  = 0.9677 A˚. In
both cases, crystals were cryoprotected by addition of
20% (v/v) glycerol to the crystallization solution, flash-
cooled at 100 K in supercooled N2 gas and maintained
at this temperature during the data collection. Thrombin–
NU172–K dataset was processed using HKL2000 (33),
while that of thrombin–NU172–Na using iMOSFLM (34)
and POINTLESS/AIMLESS (35,36).
Crystals of thrombin-NU172-K and thrombin-NU172-
Na belong to the orthorhombic space group I222 and
diffract X-rays up to 2.50 or 2.80 A˚ resolution, respectively.
Matthews’ coefficient calculations suggested the presence of
a 1:1 complex in the asymmetric unit and a solvent content
of 74.7% in thrombin–NU172–K complex and 76.1% in
thrombin–NU172–Na complex. Detailed statistics on data
collection are reported in Supplementary Table S1.
The phase problem was solved by molecular replacement
using Phaser (37). The coordinates of the native protein
(PDB code: 1PPB) (38) were utilized as search model. The
starting model was subjected to few cycles of rigid body
refinement followed by several cycles of coordinate mini-
mization and B-factor refinement using REFMAC5 pro-
gram (39). Analysis of Fourier difference maps, calculated
with (Fo – Fc) and (2Fo – Fc) coefficients, andmanual model
building performed with WinCoot program (40), allowed
the rebuilding of the whole aptamer, of a sugar chain at the
N-glycosylation site on thrombin, the positioning of ions
and of several water molecules.
The finalRfactor/Rfree valueswere 16.9/20.5 and 15.9/20.3
for thrombin-NU172-K and thrombin-NU172-Na com-
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plexes, respectively. Detailed statistics of the refinement are
reported in Supplementary Table S2.
Structural analysis
3DNA-dssr (41) was used to calculate local and over-
all geometric parameters of the aptamer. The Superpose
program (42) from CCP4 package (43) was used to cal-
culate root-mean-square deviations (RMSD). Features of
the thrombin-NU172 interface and interactions between
the two molecules were calculated by PISA (44), Contact
(CCP4 package) (43) and CoCoMaps (45) programs. All
the results were verified by visual inspection of the structure
with WinCoot (40).
Molecular graphics figures were prepared with PyMOL
(DeLano Scientific, Palo Alto, CA, USA). The coordi-
nates of the structures were deposited in the Protein Data
Bank (codes 6EVV and 6GN7 for thrombin-NU172-K and
thrombin-NU172-Na, respectively).
Circular dichroism measurements
Oligonucleotides were suspended in K buffer at a concen-
tration ranging between 1 and 40 M and annealed, as
reported above. CD spectra were recorded on a Jasco J-
715 spectropolarimeter equipped with a Peltier tempera-
ture control, using a 1.0 or 0.1 cm path length cell. Spec-
tra were registered at 10◦C in the 210–320 nm range with
50 nm/min scanning speed, 2 s response time, 1 nm data
pitch and 2.0 nm bandwidth. Each spectrum was obtained
averaging three scans.
Gel electrophoresis (PAGE) experiment
A 20% polyacrylamide gel was prepared using 30%
acrylamide/bis-acrylamide solution (24:1). The elec-
trophoretic run was carried out in 90 mM Tris–borate
buffer pH 8.0 and 20 mM EDTA (TBE buffer) on a 20
× 20 cm slab, at 4◦C, by applying to the heads of the
electrophoresis cell a 120 V voltage. For loading, 30 l of
40 M oligonucleotide sample, annealed in K buffer, were
added to 20 l of loading buffer (TBE buffer and 20%
(v/v) glycerol). After a 4 h run time, bands were visualized
by UV shadowing.
Anticoagulant activity experiments
Evaluation of the anticoagulant activity of TBA, NU172
and the mutants Des NU172 and TBA GT (Supplemen-
tary Figure S1) was performed by means of light scattering
(LS) experiments monitoring the increase of the light scat-
tered intensity upon conversion of fibrinogen to fibrin catal-
ysed by thrombin (46). LS measurements were carried out
with a home-made instrument. A 1.2 M solution of fib-
rinogen in Phosphate Buffered Saline (PBS) was placed in a
LS cuvette to which the oligonucleotide was added and left
to equilibrate in the instrument for 20 min. Then, throm-
bin was added up to a final concentration of 5 nM and the
light scattered intensity was registered every 20 s for at least
2 h. In the case of NU172 longer observation times were
required. Each oligonucleotide, annealed in K buffer, was
added to fibrinogen solutions before addition of thrombin
at a concentration such that thrombin:oligonucleotide mo-
lar ratio was either 1:1, 1:2 or 1:5. All the experiments were
performed in triplicate. Comparison of the anticoagulant
activities was performed by plotting the normalized scat-
tered intensity nI
nI = I − I0
I0
as a function of time and by linearly fitting the initial in-
crease of nI upon the lag time. The slopes of the fitted lines
give an estimation of the coagulation rate. The thrombin
inhibiting properties of the different oligonucleotides were
evaluated by calculating the ratio between the coagulation
rate in the exclusive presence of thrombin and that in the
presence of thrombin and oligonucleotides.
RESULTS
Crystal structure of the thrombin-NU172 complex
Orthorhombic I222 crystals with one 1:1 protein–aptamer
complex (Figure 1A and Supplementary Figure S3) in
the asymmetric unit were grown either in the presence
of K+ (thrombin–NU172–K) or in the presence of Na+
(thrombin–NU172–Na). They are practically isomorphous
and diffract X-rays up to 2.50 and 2.80 A˚ resolution, re-
spectively. The two independently refined complexes, within
the experimental errors, do not show significant differences
and, therefore, only thrombin–NU172–K complex is anal-
ysed in detail.
As expected, the aptamer binding does not substantially
modify the thrombin structure. After superposition of the
C heavy chain and that of the PPACK inhibited enzyme
(PDB code: 1PPB) (38) the value of RMSD is only 0.34
A˚. The only structural novelty is the long N-linked sugar
chain attached to Asn60G residue (Supplementary Figure
S4) that is clearly visible in the electron density map of the
complex.
NU172 structural features
Fourier difference maps showed continuous electron den-
sity that allowed to build the whole oligonucleotide (Sup-
plementary Figure S5). The refined model reveals the pres-
ence of the expected duplex and quadruplex domains (47),
enchained to each other with interesting new features. In
particular, the quadruplex domain (residues 7–21) is ar-
ranged in a chair-like anti-parallel fold, with guanines 8,
11, 17, 20 and 7, 12, 16, 21 forming G-tetrad I and II, re-
spectively, and three edge-wise loops, TT (Thy9-Thy10), GT
(Gua18-Thy19) and GTA (Gua13-Thy14-Ade15). A potas-
sium ion is sandwiched between the two tetrads (Figure
1A). The quadruplex motif is very similar to that of TBA
(Figure 1B) and its variants (19,29,31), which is formed by
two G-tetrads (guanines 2, 5, 11, 14 for tetrad I and 1, 6,
10, 15 for tetrad II), surrounded by a TGT loop on one
side and two TT loops on the opposite side. Differently
from the analogous TGT loop of TBA-like aptamers that
is highly mobile (19,29,31), the GTA loop is particularly
well defined. In the latter, Gua13 is hydrogen bonded to
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Figure 1. On the left, surface/cartoon representations of thrombin-NU172-K (A) and thrombin-TBA-K (PDB code: 4DII) (B) complexes. Thrombin is
coloured in blue, NU172 is coloured in green and TBA is coloured in black. On the right, view of the two tetrads along the G-quadruplex axis of the two
aptamers. The omit Fo – Fc electron density map (orange) of the potassium ion (magenta) in NU172 is contoured at 3.0  level.
Gua18 of the GT loop (Figure 2), a residue that replaces
the thymine of the TBA-like aptamers, moreover Thy14 and
Ade15 form reverse Hoogsteen base pairs with Ade6 and
Thy5, respectively. Remarkably, Ade6 also participates to
two non-linear Watson-Crick hydrogen bonds with Thy22,
thus creating a TAT triad (Thy22/Ade6/Thy14). This triad
and the base-pair Thy5/Ade15 mediate the transition from
the quadruplex to the duplex domain, creating a continuous
stacking of bases from one domain to the other. The du-
plex region of NU172 is composed by four Watson–Crick
base pairs (Cyt1/Gua26, Gua2/Cyt25, Cyt3/Gua24 and
Cyt4/Gua23), which define a regular B-type helix (Figure
2 and Supplementary Figure S6).
Thrombin-NU172 interface
Resembling TBA and its variants (19,28,29,31,48,49), the
two-residue loops of the G-quadruplex domain act as a
pincer-like system that captures the protruding region of ex-
osite I (Figure 1 and Supplementary Figure S7). However,
recognition of exosite I by NU172 presents interesting new
features. Indeed, in addition to the two-residue TT and GT
loops, the three-residue GTA loop of the G-quadruplex is
also involved in the binding. On the other hand, the duplex
domain makes no contacts with the thrombin surface.
Focusing on exosite I, it can be described as formed by
two sub-regions, referred to as A and B, respectively (48).
In the former, a hydrophobic crevice on the protein sur-
face forms a well-shaped joint that interlocks the Gua18–
Thy19 loop. As mentioned above, Gua18 shares two hydro-
gen bonds with Gua13 of GTA loop. The strong interac-
tion fixes Gua13 in a position most favourable to interact
with Arg75, whose guanidinium group is fully surrounded
by NU172 side chains and, in addition to Gua13, is hydro-
gen bonded to Thy19 and Thy10 (Figure 3A and B). This
network of side chains contacts recruits the three-residue
loop of the G-quadruplex for the binding to thrombin and
represents a unique feature of NU172 that significantly en-
larges the contact area between NU172 and the A-region,
compared to the complexes between thrombin and other
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Figure 2. Cartoon representation of NU172 architecture (duplex in light green, quadruplex in dark green and the junction in lemon-green). On the left,
view of the TAT triad along the G-quadruplex axis. On the right, view of the interactions between guanine 13 (GTA loop) and guanine 18 (GT loop). The
omit Fo – Fc electron density maps (orange) are contoured at 3.0  level. Dashed lines represent hydrogen bonds.
Figure 3. Interface interactions between thrombin (in blue) and NU172 (in green). (A) Hydrogen bonds (dashed lines) connecting Arg75 to Gua13,
Thy19 and Thy10. (B) Space-filling representation of Arg75 side chain and its environment. (C) – stacking between Thy9 and Tyr76.
aptamers (Table 1 and Supplementary Table S3). As far as
the TT loop is concerned, it interacts with B-region, which
is less extended than theA-region (48), through a- stack-
ing between Thy9 and Tyr76 (Figure 3C, Table 1 and Sup-
plementary Table S3).
It should be recalled that TBA can bind thrombin in two
different ways that are practically isoenergetic. In one case,
a TT loop interacts with the A-region and the second TT
loop interacts with the B-region, in the second case these
interactions are reversed through a rotation of 180◦ about
the pseudo twofold axis of the aptamer (48,50). In the case of
NU172, the replacement of a T for a G in one TT loop dis-
criminates between the two binding modes, strongly favour-
ing the one inwhich theGT loop interacts with theA-region
of the protein.
Finally, it is worth to stress that protein-aptamer con-
tacts do not change in the thrombin–NU172–Na structure
(Supplementary Table S3), in contrast to what observed
for thrombin-TBA complex (19), where the replacement of
K+ with Na+ causes a small reorganization of the protein–
aptamer interface that may explain the observed modifica-
tion of the aptamer functionality.
Characterization of NU172 mutants
In order to gain a deeper knowledge of the structural fea-
tures that are at the basis of the improved affinity of NU172
with respect to TBA-like aptamers, two mutants were con-
structed and characterized in solution. In particular, atten-
tion was focused on the role of the GT loop and that of
the duplex module (Supplementary Figure S1), by studying
the mutant TBA GT of TBA with a T→G substitution in
the appropriate loop (Thy12–Thy13), and the deletion mu-
tant Des NU172, in which only the G-quadruplex domain
of NU172 is conserved. In particular, we tested their aggre-
gation status, folding in solution and in vitro anticoagulant
activity in comparison to TBA and NU172.
The polyacrylamide native gel electrophoretogram (Fig-
ure 4) exhibits a single band for TBA and NU172 (lanes 1
and 2, respectively), indicating the presence of a single struc-
tural species, with a relativemobility in fully agreement with
their size. Vice versa, several bands are observed in lanes
3 and 4, suggesting that Des NU172 and TBA GT form
non-homogeneous solution containing species with differ-
ent molecularity.
Similar conclusions can be drawn by the CD spectra
recorded under the same conditions (Figure 5A). While the
spectra of TBA and NU172 show features that indicate the
presence of a canonical G-quadruplex structure, those of
Des NU172 and TBA GT suggest conformational hetero-
geneity. Interestingly, at lower concentration (1 M) the
spectrum of TBA GT becomes superimposable to that of
TBA, whereas the spectrum of Des NU172 still indicates
the presence of more than one conformer (Figure 5B).
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Table 1. Interface area between protein and aptamer in thrombin–TBA–K (PDB code: 4DII) and thrombin–NU172–K complexes.
TBA NU172
Whole interface 543 A˚2 590 A˚2
Thrombin A-region 282 A˚2 (Thy3–Thy4)a 324 A˚2 (Gua13–Gua18–Thy19)a
Thrombin B-region 183 A˚2 (Thy12–Thy13)a 215 A˚2 (Thy9–Thy10)a
aIn parentheses the aptamer nucleobases that make interactions with thrombin exosite I in A- and B-region.
Figure 4. Gel electrophoresis analysis of (1) TBA, (2) NU172, (3)
Des NU172 and (4) TBA GT. The 40 M oligonucleotide samples were
annealed the day before the run in 10 mM potassium phosphate buffer pH
7.4 and 100 mM KCl.
These CD data, together with the electrophoretic re-
sults, indicate that the substitution of Thy12 with a guanine
residue in the TT loop of TBA and, in particular, the dele-
tion of the duplex region in NU172 induce a marked desta-
bilization of the antiparallel unimolecular G-quadruplex
conformation and an increase in its conformational flexi-
bility.
Anticoagulant activity of NU172 and its mutants
The anticoagulant activities were evaluated following the
thrombin catalysed conversion of fibrinogen to fibrin by
means of LS experiments (46). In Figure 6 the intensity of
the scattered light, which measures the progression of fib-
rin formation, is reported as a function of time in the ab-
sence and in the presence of the oligonucleotides (1:2 throm-
bin:oligonucleotide molar ratio). The various curves clearly
indicate the inhibition of thrombin coagulation activity ex-
erted by all tested oligonucleotides. Remarkably, NU172
acts as a very potent thrombin inhibitor. Indeed, for a rather
long time no change of the intensity is observed. In the case
of the other oligonucleotides, the increase of the intensity
can be noted much sooner and in few hours the samples
gelifies, similarly to the samples in which only thrombin is
present.
An estimate of the anticoagulant activity of each oligonu-
cleotide was obtained by calculating the ratio between the
initial slope of the normalized scattered intensities in the
absence and in the presence of the oligonucleotide (Supple-
mentary Table S4). The results show that NU172 is able to
decrease the coagulation rate of about two orders of mag-
nitude already at 1:1 thrombin:oligonucleotide molar ratio,
while the two mutants are thrombin inhibitors as effective
as TBA.
Figure 5. Overlapping of CD spectra of TBA (black), NU172 (green),
Des NU172 (blue) and TBA GT (magenta) in 10 mM potassium phos-
phate buffer pH 7.4 and 100 mM KCl. Spectra were recorded at 10◦C on
40 M (A) or 1 M (B) annealed oligonucleotide samples.
DISCUSSION
A fast and cost-efficient drug optimization program re-
quires detailed structural information on the interaction be-
tween the pharmacologically active molecule and its tar-
get. In this respect, we have investigated the recognition be-
tween human alpha-thrombin and NU172, the only anti-
thrombin aptamer currently in Phase II clinical trials for
short-term anticoagulation (3,11,24,25). The crystal struc-
ture of the thrombin–NU172 complex reveals that the ap-
tamer adopts a mixed duplex/quadruplex structure whose
spine is a continuous stacking of bases from the duplex
to the quadruplex region. Notably, a reverse Hoogsteen
base pair and a base triad (TAT), involving residues of the
quadruplex GTA loop, form the sharp transition between
the two structural domains. It is worth to note that a TAT
triad has been found as the junction motif between a paral-
lel G-quadruplex and an antiparallel B-duplex structure in
two duplex/quadruplex telomeric repeats, where it directly
mediates the transition from one domain to the other (51).
In our structure, TAT joins an antiparallel B-duplex with
an antiparallel G-quadruplex, thus indicating that the triad
is a versatile motif able to connect quadruplex and duplex
domains with different topologies with no loss of stacking
between adjacent bases.
The intramolecular compactness of the duplex/quadr
uplex architecture of NU172 generates a boundary sur-
face particularly well suited to interact with thrombin ex-
osite I in comparison to other thrombin-aptamer com-
plexes (Supplementary Table S3) (19,29,31,48). The inter-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/22/12177/5144158 by U
niw
ersytet Jagiellonsky w
 Krakow
ie user on 13 M
arch 2019
Nucleic Acids Research, 2018, Vol. 46, No. 22 12183
Figure 6. Coagulation curves of fibrinogen in the presence of thrombin
and different oligonucleotides (TBA; NU172; Des NU172 and TBA GT,
see inset for details).
face involves not only the two-residue loops, but also the
GTA loop that in turn is directly involved in the stabi-
lization of the duplex/quadruplex organization. Indeed,
Gua13, the only GTA residue that does not participate to
the duplex/quadruplex connection, forms a GG base pair
with Gua18 of the GT loop, further locking the quadru-
plex structure and stiffening the assembly of the nucleotide
bases around the guanidium group ofArg75 (Figure 3A and
B). This double role qualifies GTA loop as a basic struc-
tural feature that confers toNU172 the improved functional
properties in its interaction with thrombin. The compact-
ness of the overall structure can also explain the observed
relative insensitivity of the complex versus the K+/Na+
exchange, differently from what found in the case of the
thrombin–TBA complex (19).
The observed strict interaction between duplex and
quadruplex domains corroborates the results of a thorough
investigation (47) on the conformational stability of bimod-
ular anti-thrombin aptamers, which indicates a one-step un-
folding mechanism for NU172, similar to that of RE31, an
aptamer that presents a continuous stacking spine as well
(31). Moreover, the characterization of Des NU172 and
TBA GT mutants underlines the importance of the duplex
domain, confirming the key role of this motif in the stabi-
lization of the appropriate antiparallel G-quadruplex fold-
ing and in the organization of the inter-domains region that
allows the participation of the GTA loop to the thrombin
binding. Indeed, anticoagulant experiments in physiologi-
cal mimicking conditions highlight the excellent inhibitory
properties of NU172 that are about two orders of magni-
tude higher than those of TBA and both Des NU172 and
TBA GT mutants. Moreover, they also prove that the pres-
ence of Gua13 and/or Gua18 in the absence of the duplex
motif is not sufficient to reach the anticoagulant activity ob-
served for NU172.
The finding that, despite the conformational heterogene-
ity ofDes NU172 at the oligonucleotide concentration used
in the experiments, its anticoagulant activity is similar to
that of TBA and TBA GT could be ascribed to the throm-
bin ability to act as molecular chaperone (19,52), inducing
the oligonucleotide to adopt a unimolecular antiparallel G-
quadruplex conformation.
In conclusion, the structural characterization of
thrombin-NU172 complex and some related mutants
strongly indicates that the interesting properties of NU172
are associated to the concomitant presence of several mo-
tifs. Indeed, the coexistence of a duplex and a quadruplex
domain interlocked through the TAT triad, the presence
of guanines in two loops of the quadruplex structure
and the GG inter-loop base pair are features that, taken
together, synergistically cooperate in determining an
overall structure capable to efficiently interact with the
thrombin surface. We believe that these results represent
an instructive example of the way in which several local
features may concur to produce interesting new properties
and should be taken in consideration particularly for the
modification or the design of new aptamers, a class of
substances that display an elevated structural flexibility.
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